Russian Pharmaceutical Market Outlook to 2017
The pharmaceutical industry in Russia finally seems ready for a change. With the government adopting ‘Strategy 2020’ to improve the production capacity of the Russian pharma sector, pharmaceutical companies have started investing in the Russian market. As a result, the Russian pharmaceutical industry has started growing at a steady rate. In future, various factors such as increased support from the government, rise in expenditure on healthcare, and noteworthy growth in investments made by the private players will continue to boost the market.
According to our report, “Russian Pharmaceutical Market Outlook to 2017”, the pharmaceutical market is anticipated to grow at a CAGR of around 11% during 2012-2017. Essentially, RNCOS’ report provides an exhaustive study of the Russian pharmaceuticals market. A section has been dedicated to the industry’s infrastructure which focuses on the emerging pharmaceutical clusters in Russia and the role they will play in shaping the market.
The market has been segmented as per various levels such as the state segment, the commercial segment and the parapharmaceutical segment. Subsequently, markets for these segments have been further broken down on the basis of their ATC groups. The drugs import scenario for each segment has also been provided. Moreover, major distributors of the pharmaceutical industry have been highlighted along with their respective market shares.
The report provides an insight into the clinical trial scenario and reveals that almost twice the number of clinical trials has been approved in 2012 as compared to 2011. This is indicative of the increasing government support in order to boost domestic innovation. Further, current market driving forces and roadblocks have been discussed. On the one hand, increasing support from the government can be seen as a ray of hope for providing the market a necessary boost, while on the other corruption, deep rooted at every level, may act as a deterrent.
The report also focuses on the current regulatory reforms such as the transition to GMP standards, promotion, and procurement of pharmaceuticals which will play important roles in sculpting the market. Lastly, detailed analysis of major pharmaceutical players within Russia has been given with emphasis on strengths and weaknesses as well as the recent developments of each player.
According to our report, “Russian Pharmaceutical Market Outlook to 2017”, the pharmaceutical market is anticipated to grow at a CAGR of around 11% during 2012-2017. Essentially, RNCOS’ report provides an exhaustive study of the Russian pharmaceuticals market. A section has been dedicated to the industry’s infrastructure which focuses on the emerging pharmaceutical clusters in Russia and the role they will play in shaping the market.
The market has been segmented as per various levels such as the state segment, the commercial segment and the parapharmaceutical segment. Subsequently, markets for these segments have been further broken down on the basis of their ATC groups. The drugs import scenario for each segment has also been provided. Moreover, major distributors of the pharmaceutical industry have been highlighted along with their respective market shares.
The report provides an insight into the clinical trial scenario and reveals that almost twice the number of clinical trials has been approved in 2012 as compared to 2011. This is indicative of the increasing government support in order to boost domestic innovation. Further, current market driving forces and roadblocks have been discussed. On the one hand, increasing support from the government can be seen as a ray of hope for providing the market a necessary boost, while on the other corruption, deep rooted at every level, may act as a deterrent.
The report also focuses on the current regulatory reforms such as the transition to GMP standards, promotion, and procurement of pharmaceuticals which will play important roles in sculpting the market. Lastly, detailed analysis of major pharmaceutical players within Russia has been given with emphasis on strengths and weaknesses as well as the recent developments of each player.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. PHARMACEUTICAL INDUSTRY INFRASTRUCTURE OVERVIEW
4. PHARMACEUTICAL MARKET OUTLOOK TO 2017
4.1 Market Size & Growth
4.2 Branded and Generics Drugs
4.3 Commercial Drugs Market
4.3.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
4.3.2 Leading Companies
4.3.3 Leading Drugs
4.3.4 Drugs Import Scenario
4.4 State Segment
4.4.1 Drug Reimbursement Program (DLO)
4.4.1.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
4.4.1.2 Leading Companies
4.4.1.3 Leading Drugs
4.4.1.4 Drugs Import Scenario
4.4.2 Hospital Segment
4.4.2.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
4.4.2.2 Leading Companies
4.4.2.3 Leading Drugs
4.4.2.4 Drugs Import Scenario
4.5 Parapharmaceutical Market
4.5.1 Nutritional Supplements Market
4.5.2 Leading Companies
4.5.3 Drugs Import Scenario
4.6 Pharmaceutical Distribution System
5. CLINICAL TRIALS MARKET OUTLOOK
6. INDUSTRY ANALYSIS
6.1 Market Driving Forces
6.1.1 Government Support for Industry Development
6.1.2 Higher FDI Inflows
6.1.3 Increasing Share of Expensive Drugs
6.1.4 Rise in Purchasing Power: Better Affordability
6.2 Industry Roadblocks
7. REGULATORY ENVIRONMENT
7.1 Current Reforms
7.2 Objective and Impact of Proposed Laws and Legislations
8. COMPETITIVE LANDSCAPE
8.1 Sanofi-Aventis
8.1.1 Business Overview
8.1.2 Product Portfolio
8.1.3 Key Financials
8.1.4 Strengths and Weaknesses
8.1.5 Recent Developments
8.2 Novartis Pharma ZAO
8.2.1 Business Overview
8.2.2 Product Portfolio
8.2.3 Key Financials
8.2.4 Strengths and Weaknesses
8.3 Roche Moscow Ltd.
8.3.1 Business Overview
8.3.2 Product Portfolio
8.3.3 Key Financials
8.3.4 Strengths and Weaknesses
8.3.5 Recent Developments
8.4 Teva Pharmaceutical
8.4.1 Business Overview
8.4.2 Product Portfolio
8.4.3 Key Financials
8.4.4 Recent Developments
8.5 Pharmstandard JSC
8.5.1 Business Overview
8.5.2 Product Portfolio
8.5.3 Strengths and Weaknesses
8.5.4 Recent Developments
2. RESEARCH METHODOLOGY
3. PHARMACEUTICAL INDUSTRY INFRASTRUCTURE OVERVIEW
4. PHARMACEUTICAL MARKET OUTLOOK TO 2017
4.1 Market Size & Growth
4.2 Branded and Generics Drugs
4.3 Commercial Drugs Market
4.3.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
4.3.2 Leading Companies
4.3.3 Leading Drugs
4.3.4 Drugs Import Scenario
4.4 State Segment
4.4.1 Drug Reimbursement Program (DLO)
4.4.1.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
4.4.1.2 Leading Companies
4.4.1.3 Leading Drugs
4.4.1.4 Drugs Import Scenario
4.4.2 Hospital Segment
4.4.2.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
4.4.2.2 Leading Companies
4.4.2.3 Leading Drugs
4.4.2.4 Drugs Import Scenario
4.5 Parapharmaceutical Market
4.5.1 Nutritional Supplements Market
4.5.2 Leading Companies
4.5.3 Drugs Import Scenario
4.6 Pharmaceutical Distribution System
5. CLINICAL TRIALS MARKET OUTLOOK
6. INDUSTRY ANALYSIS
6.1 Market Driving Forces
6.1.1 Government Support for Industry Development
6.1.2 Higher FDI Inflows
6.1.3 Increasing Share of Expensive Drugs
6.1.4 Rise in Purchasing Power: Better Affordability
6.2 Industry Roadblocks
7. REGULATORY ENVIRONMENT
7.1 Current Reforms
7.2 Objective and Impact of Proposed Laws and Legislations
8. COMPETITIVE LANDSCAPE
8.1 Sanofi-Aventis
8.1.1 Business Overview
8.1.2 Product Portfolio
8.1.3 Key Financials
8.1.4 Strengths and Weaknesses
8.1.5 Recent Developments
8.2 Novartis Pharma ZAO
8.2.1 Business Overview
8.2.2 Product Portfolio
8.2.3 Key Financials
8.2.4 Strengths and Weaknesses
8.3 Roche Moscow Ltd.
8.3.1 Business Overview
8.3.2 Product Portfolio
8.3.3 Key Financials
8.3.4 Strengths and Weaknesses
8.3.5 Recent Developments
8.4 Teva Pharmaceutical
8.4.1 Business Overview
8.4.2 Product Portfolio
8.4.3 Key Financials
8.4.4 Recent Developments
8.5 Pharmstandard JSC
8.5.1 Business Overview
8.5.2 Product Portfolio
8.5.3 Strengths and Weaknesses
8.5.4 Recent Developments
LIST OF FIGURES:
Figure 4-1: Pharmaceutical Market (Trillion RUB), 2012-2017
Figure 4-2: Pharmaceutical Market Breakup by Segment (%), 2012-2017
Figure 4-3: Share of Branded and Generics in Pharmaceutical Market (2012)
Figure 4-4: Commercial Drugs Market (Trillion RUB), 2012-2017
Figure 4-5: Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Value (2011 & 2012)
Figure 4-6: State Segment Drugs Market (Billion RUB), 2012-2017
Figure 4-7: Disbursement under DLO Program (Billion RUB), 2011-2013
Figure 4-8: Share of Imported & Domestic Drugs under DLO Program by Sales Value (2011-2013)
Figure 4-9: Share of Imported & Domestic Drugs under Hospital Segment by Sales Value (2011-2013)
Figure 4-10: Parapharmaceutical Market (Billion RUB), 2012-2017
Figure 4-11: Nutritional Supplements Market (Billion RUB), 2011-2013
Figure 4-12: Share of Imported & Domestic Nutritional Supplements by Sales Value (2012)
Figure 5-1: Number of Clinical Trials Approved (2010-2012)
Figure 5-2: Clinical Trials by Therapeutic Area (%), 2012
Figure 5-3: Clinical Trials by Sponsor Country (%), 2012
Figure 6-1: Share of Pharmaceuticals' Sales by Price Bracket (2011 & 2012)
Figure 6-2: Gross National Income per Capita (‘000 US$), 2009-2012
Figure 6-3: Global - Distribution of Counterfeit Medicines (%), 2012
Figure 4-1: Pharmaceutical Market (Trillion RUB), 2012-2017
Figure 4-2: Pharmaceutical Market Breakup by Segment (%), 2012-2017
Figure 4-3: Share of Branded and Generics in Pharmaceutical Market (2012)
Figure 4-4: Commercial Drugs Market (Trillion RUB), 2012-2017
Figure 4-5: Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Value (2011 & 2012)
Figure 4-6: State Segment Drugs Market (Billion RUB), 2012-2017
Figure 4-7: Disbursement under DLO Program (Billion RUB), 2011-2013
Figure 4-8: Share of Imported & Domestic Drugs under DLO Program by Sales Value (2011-2013)
Figure 4-9: Share of Imported & Domestic Drugs under Hospital Segment by Sales Value (2011-2013)
Figure 4-10: Parapharmaceutical Market (Billion RUB), 2012-2017
Figure 4-11: Nutritional Supplements Market (Billion RUB), 2011-2013
Figure 4-12: Share of Imported & Domestic Nutritional Supplements by Sales Value (2012)
Figure 5-1: Number of Clinical Trials Approved (2010-2012)
Figure 5-2: Clinical Trials by Therapeutic Area (%), 2012
Figure 5-3: Clinical Trials by Sponsor Country (%), 2012
Figure 6-1: Share of Pharmaceuticals' Sales by Price Bracket (2011 & 2012)
Figure 6-2: Gross National Income per Capita (‘000 US$), 2009-2012
Figure 6-3: Global - Distribution of Counterfeit Medicines (%), 2012
LIST OF TABLES:
Table 4-1: Commercial Drugs Sales Structure of ATC Groups (2012)
Table 4-2: Leading Companies in Commercial Drugs Market by Sales (Million RUB), 2012
Table 4-3: Leading Drugs in Commercial Drugs Market by Sales (Million RUB), 2012
Table 4-4: Drugs Sales Structure of ATC Groups under DLO Program (2012)
Table 4-5: Leading Companies under DLO Program by Sales (Million RUB), 2012
Table 4-6: Leading Drugs under DLO Program by Sales (Million RUB), 2012
Table 4-7: Drugs Sales Structure of ATC Groups under Hospital Segment (2012)
Table 4-8: Leading Companies under Hospital Segment by Sales (Million RUB), 2012
Table 4-9: Leading Drugs under Hospital Segment by Sales (Million RUB), 2012
Table 4-10: Leading Companies under Nutritional Supplement Segment by Sales (Million RUB), 2012
Table 4-11: Leading Distributors in Pharmaceutical Market by Sales (Million RUB), 2012
Table 8-1: Sanofi-Aventis - Key Financials (Million €), 2010-2012
Table 8-2: Sanofi-Aventis - Strengths & Weaknesses
Table 8-3: Novartis - Key Financials (Million US$), 2010-2012
Table 8-4: Novartis - Strengths & Weaknesses
Table 8-5: Pharmstandard - Strengths & Weaknesses
Table 4-1: Commercial Drugs Sales Structure of ATC Groups (2012)
Table 4-2: Leading Companies in Commercial Drugs Market by Sales (Million RUB), 2012
Table 4-3: Leading Drugs in Commercial Drugs Market by Sales (Million RUB), 2012
Table 4-4: Drugs Sales Structure of ATC Groups under DLO Program (2012)
Table 4-5: Leading Companies under DLO Program by Sales (Million RUB), 2012
Table 4-6: Leading Drugs under DLO Program by Sales (Million RUB), 2012
Table 4-7: Drugs Sales Structure of ATC Groups under Hospital Segment (2012)
Table 4-8: Leading Companies under Hospital Segment by Sales (Million RUB), 2012
Table 4-9: Leading Drugs under Hospital Segment by Sales (Million RUB), 2012
Table 4-10: Leading Companies under Nutritional Supplement Segment by Sales (Million RUB), 2012
Table 4-11: Leading Distributors in Pharmaceutical Market by Sales (Million RUB), 2012
Table 8-1: Sanofi-Aventis - Key Financials (Million €), 2010-2012
Table 8-2: Sanofi-Aventis - Strengths & Weaknesses
Table 8-3: Novartis - Key Financials (Million US$), 2010-2012
Table 8-4: Novartis - Strengths & Weaknesses
Table 8-5: Pharmstandard - Strengths & Weaknesses
